Search / 10 results found

from
to
  • Updated

BOSTON, Nov. 11, 2021 /PRNewswire/ -- Oncoheroes Biosciences Inc. ("Oncoheroes"), a biotech focused on advancing new therapies for childhood cancer, has out-licensed worldwide the adult rights to Notable Labs, Inc. ("Notable"), a clinical-stage predictive precision medicine company. Under the terms of this agreement, Oncoheroes will retain the license for the development and commercialization of volasertib for pediatric cancers and continue its commitment towards childhood cancer. Notable will have exclusive rights to develop and commercialize volasertib in adult cancer indications. Financial details of this deal are not disclosed.

  • Updated

LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a Boston-based non-profit accelerating antibacterial research. This extended financing will support the ongoing development of a novel antibiotic for the treatment of Neisseria gonorrhoeae infections, including those caused by multi-resistant strains. This extension of over $1 million will allow the completion of preliminary toxicology studies needed to determine the doses for pivotal toxicology research as well as optimize the production steps of the development candidate. This is a step towards the development of an affordable, quality product for human use and eventual clinical research. This funding succeeds the previous rounds over the last 4 years supporting earlier research, totaling up to $4 million since 2017.

  • Updated

LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /CNW/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a Boston-based non-profit accelerating antibacterial research. This extended financing will support the ongoing development of a novel antibiotic for the treatment of Neisseria gonorrhoeae infections, including those caused by multi-resistant strains. This extension of over $1 million will allow the completion of preliminary toxicology studies needed to determine the doses for pivotal toxicology research as well as optimize the production steps of the development candidate. This is a step towards the development of an affordable, quality product for human use and eventual clinical research. This funding succeeds the previous rounds over the last 4 years supporting earlier research, totaling up to $4 million since 2017.

  • Updated

LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its antibiotic program, Debio 1453, by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a Boston-based non-profit accelerating antibacterial research. This extended financing will support the ongoing development of a novel antibiotic for the treatment of Neisseria gonorrhoeae infections, including those caused by multi-resistant strains. This extension of over $1 million will allow the completion of preliminary toxicology studies needed to determine the doses for pivotal toxicology research as well as optimize the production steps of the development candidate. This is a step towards the development of an affordable, quality product for human use and eventual clinical research. This funding succeeds the previous rounds over the last 4 years supporting earlier research, totaling up to $4 million since 2017.

  • Updated

BRAINTREE, Mass., Oct. 7, 2021 /PRNewswire/ -- Planon is proud to be named a 'Leader' in the Computerized Maintenance Management Systems (CMMS) category and in the Facility Management (CAFM) Applications category in two IDC MarketScape reports – IDC MarketScape: Worldwide SaaS CMMS Application 2021 Vendor Assessment and IDC MarketScape: Worldwide SaaS Facility Management Application 2021 Vendor Assessment. In the assessments, the IDC MarketScape recognizes Planon's open platform strategy and ecosystem, digital visualization capabilities and global presence as major strengths that Planon delivers to its customers.

  • Updated

BRAINTREE, Mass., Oct. 7, 2021 /CNW/ -- Planon is proud to be named a 'Leader' in the Computerized Maintenance Management Systems (CMMS) category and in the Facility Management (CAFM) Applications category in two IDC MarketScape reports – IDC MarketScape: Worldwide SaaS CMMS Application 2021 Vendor Assessment and IDC MarketScape: Worldwide SaaS Facility Management Application 2021 Vendor Assessment. In the assessments, the IDC MarketScape recognizes Planon's open platform strategy and ecosystem, digital visualization capabilities and global presence as major strengths that Planon delivers to its customers.